Market Overview

Global Targeted DNA RNA Sequencing Market size and share is currently valued at USD 12.02 billion in 2024 and is anticipated to generate an estimated revenue of USD 70.79 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 19.4% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034

Targeted DNA/RNA sequencing refers to next-generation sequencing (NGS) methods that focus on specific genes or genomic regions of interest, as opposed to whole-genome or whole-transcriptome sequencing. This approach enhances efficiency and lowers costs while providing deep coverage and high accuracy, making it ideal for gene expression profiling, mutational analysis, and biomarker discovery.

Key Market Growth Drivers

  1. Rising Demand for Precision Medicine

The global healthcare sector is shifting from one-size-fits-all treatment paradigms to personalized therapies based on individual genetic profiles. Targeted DNA/RNA sequencing plays a pivotal role in identifying mutations and molecular markers that inform tailored treatment plans—especially in cancers such as breast, lung, and colorectal cancer.

  1. Expanding Applications in Oncology

With cancer incidence rising worldwide, targeted sequencing is now a routine component in cancer research and diagnostics. It enables detection of somatic mutations, fusions, and copy number variations critical for prognosis and therapy selection. NGS panels targeting oncogenes and tumor suppressor genes have become essential in both solid tumors and hematologic malignancies.

  1. Growth in Infectious Disease Surveillance

The COVID-19 pandemic highlighted the importance of genomic surveillance in identifying viral mutations and variants. Targeted sequencing is increasingly used for pathogen detection, antimicrobial resistance profiling, and outbreak tracking, expanding its relevance beyond traditional human genomics.

  1. Technological Advancements in NGS

Rapid evolution in next-generation sequencing platforms has made targeted sequencing faster, cheaper, and more scalable. Newer platforms offer enhanced throughput and automation, allowing labs to process more samples with higher accuracy and minimal hands-on time. Miniaturized and benchtop sequencers are also driving adoption in small and mid-sized clinical laboratories.

  1. Government Funding and Genomic Initiatives

Public health initiatives like the All of Us Research Program (U.S.), 100,000 Genomes Project (UK), and GenomeAsia 100K are providing significant funding and infrastructural support to expand sequencing capabilities globally. These programs aim to map genetic variation across populations and diseases, further cementing the value of targeted approaches in large-scale studies.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/targeted-dna-rna-sequencing-market

Market Challenges

Despite strong momentum, the targeted DNA/RNA sequencing market faces several challenges:

  1. High Initial Setup Costs

Although per-sample sequencing costs have dropped, the initial investment required for NGS instruments, infrastructure, and skilled personnel remains high—posing barriers for smaller labs and institutions, especially in developing regions.

  1. Data Analysis Complexity

The data generated by NGS is vast and requires advanced bioinformatics tools and expertise to interpret. Many labs struggle with the integration of sequencing workflows with user-friendly, clinically validated software platforms for data analysis and reporting.

  1. Regulatory and Reimbursement Hurdles

Inconsistent regulatory pathways and limited reimbursement coverage for genomic testing in certain countries impede market expansion. Clinical utility and cost-effectiveness of targeted sequencing assays must be demonstrated to gain payer support.

  1. Standardization Issues

Lack of standardized protocols across laboratories and regions can lead to variability in sequencing performance and data interpretation. Harmonizing sample preparation, library construction, and data pipelines is critical for clinical reliability.

Regional Analysis

North America

North America leads the global targeted sequencing market due to robust healthcare infrastructure, widespread adoption of NGS panels, and strong research funding. The U.S., in particular, houses leading biotech firms and genomic research centers. Rising cancer incidence and favorable reimbursement policies are further catalyzing market growth.

Europe

Europe is another major player, with countries like the UK, Germany, and France leading genomics research and precision medicine initiatives. The UK’s Genomics England and France Génomique projects exemplify public-private collaborations supporting sequencing-based diagnostics. Regulatory alignment across the EU is also facilitating wider adoption in clinical settings.

Asia-Pacific

The Asia-Pacific region is expected to witness the fastest growth, driven by increasing healthcare spending, large patient populations, and expanding R&D activities. China and India are investing heavily in genomics infrastructure, while Japan remains a strong hub for innovation in molecular diagnostics and healthcare technologies.

Latin America

Countries such as Brazil and Mexico are increasingly adopting sequencing technologies, particularly for cancer diagnostics and infectious disease surveillance. However, infrastructural and economic constraints may hinder rapid expansion.

Middle East & Africa

The Middle East & Africa represent emerging markets with growing interest in genomic medicine. The UAE and Saudi Arabia have launched national genome programs, which are expected to boost adoption of targeted sequencing tools in the region.

Key Companies

Several global and regional players are driving innovation in the targeted sequencing space. These companies are focused on enhancing panel design, improving assay specificity, and streamlining workflow integration.

  1. Illumina Inc.

A dominant player in the NGS market, Illumina offers a comprehensive suite of targeted sequencing panels, library prep kits, and benchtop sequencers like the NextSeq and MiSeq platforms. The company continues to innovate in gene expression profiling and oncology applications.

  1. Thermo Fisher Scientific

Thermo Fisher provides turnkey solutions through its Ion Torrent platform, Oncomine panels, and AmpliSeq technology. The company plays a critical role in enabling amplicon sequencing for both DNA and RNA targets.

  1. Agilent Technologies

Agilent is a key provider of hybrid capture-based NGS panels and automated sample preparation systems. Its SureSelect and HaloPlex product lines are widely used in cancer genomics and inherited disease studies.

  1. Roche Sequencing Solutions

Roche offers a strong portfolio of molecular diagnostics products, including its AVENIO family of targeted sequencing kits designed for both tissue and liquid biopsy samples.

  1. Qiagen N.V.

Qiagen is focused on sample-to-insight NGS workflows, offering bioinformatics tools, custom panel design, and library prep solutions suited for translational research and diagnostics.

  1. Oxford Nanopore Technologies

Known for its portable and real-time sequencing devices, Oxford Nanopore is bringing targeted sequencing to the field and point-of-care settings. Its adaptive sampling technology enables targeted analysis on-demand without upfront panel design.

  1. Twist Bioscience

Twist’s synthetic biology expertise allows it to deliver custom high-throughput gene panels and hybrid capture solutions. Its scalable technology platform is ideal for population genomics and biomarker discovery.

Conclusion

The Targeted DNA/RNA Sequencing Market is at the forefront of the genomic revolution, bridging research and clinical applications with unparalleled precision. As personalized medicine becomes the new standard of care, demand for targeted, cost-effective, and actionable genetic insights continues to grow. With innovations in amplicon sequencing, NGS panels, gene expression profiling, and molecular diagnostics, the future of healthcare is rapidly being rewritten—one gene at a time.

More Trending Latest Reports By Polaris Market Research:

Infectious Disease Diagnostics Market

Car Camera Cleaning Systems Market

Oyster and Clam Market

Recruitment Process Outsourcing Market

3D Printing Metals Market

Ultrasound Probe Cover Market: A Sanitized Approach to Staff Efficacy and Patient Safety

Rigid Plastic Packaging Market

Food Amino Acids Market

Cell Therapy Market